Markland55 (@markland_55) profile picture

Disclaimer: my tweets aren’t intended to be investment advice

Manhattan, NY
Joined February 2020
Photo by Markland55 (@markland_55)Photo by Markland55 (@markland_55)Photo by Markland55 (@markland_55)Photo by Markland55 (@markland_55)
The volume and predictability of antisemitic attacks directed at @adamfeuerstein whenever his reporting is negative on a retail-heavy biotech name has become hard to ignore. Disagreement with his analysis of trial data, regulatory risk, or company communications is ordinary. Substituting that disagreement with references to his Jewish identity, coordinated media cabals, or dual loyalty is not. Those are recycled tropes, not arguments. They appear with enough regularity across different tickers that the pattern is no longer deniable. I’ve stayed anonymous on here for a long time. The persistence of this particular strain of bad faith is starting to make that choice feel like an unnecessary concession. I’m with you Adam $SLS $CAPR etc
8
15
1,563
$CAPR @adamfeuerstein built a career dunking on Sarepta and Doug Ingram. Now he’s running the same playbook on Capricor and deramiocel for clicks but I still defend him. Yes, the LVEF endpoint missed stat sig under the original SAP. But even under SAP 1.1 there was directional benefit on mid-level PUL, and the cardiomyopathy subgroup showed LVEF improvement. OLE data also showed slower upper limb decline. This is per the FDA and yes Linda sucks but.. For a progressive fatal disease with few options, that’s enough for approval on risk/reward, especially with cleaner safety than gene therapies already approved that had liver failure deaths. Let patients, doctors, and payers decide if it works. Real-world use will settle it faster than more AdCom fights. Please Adam find a new subject like “Will AI cure all diseases?” That’s a better debate than rehashing every imperfect rare disease trial.
2
1
40
2,242
$CAPR Ahead of the HOPE-3 data, a bunch of people were short and loud about how the science was weak, the mechanism was trash, and the trial was going to fail. Then the numbers came out positive on the primary endpoint and the stock went vertical, up several hundred percent in a day. Shorts got destroyed. Some of the loudest skeptics took real money losses while the people who just owned the setup into the readout got paid. The same dynamic is playing out again into the PDUFA. You do not need to believe Linda or love the mechanism or ignore the AdCom vote and the lawsuit. The FDA has been signaling flexibility on rare disease, Duchenne still has massive unmet need, and Capricor has a clean binary date with more long-term data in the package. That is enough for the stock to work even if the pure science bears are right on every technical point. People keep trying to win the science argument on X instead of just trading the setup. Last December showed how that ends when the catalyst hits. Capricor still looks good here.
4
1
28
2,018
The king @A_May_MD is dead , long live the king @seedy19tron !
360
Rigorous studies of deramiocel’s efficacy in @Duchenne @cardiomyopathy. Strong evidence of disease-modifying bioactivity in advanced @DMD, especially in the prespecified subgroup of HOPE-3 subjects with cardiomyopathy at baseline. Progression totally halted over one year of follow-up, with a trend towards net improvement— contrary to the relentless progression of dysfunction and scar in the placebo group. Congrats Jon Soslow, Chet Vila and team!
This weekend at the American Heart Association Scientific Sessions 2026, Dr. Jonathan Soslow of Vanderbilt received the Outstanding Research Award in Pediatric Cardiology for his presentation of the HOPE-3 cardiac results for Deramiocel in Duchenne muscular dystrophy. Congratulations, Dr. Soslow, and thank you to the patients, families and investigators who made this research possible. Read the press release: bit.ly/4BMIYM5 #AHA26 #Duchenne #DMD #ScientificSessions26 #Deramiocel $CAPR
4
17
1
80
10,009
I’ve supported $CAPR for over 5 years and I’m still long- I believe they’ll get an approval- but it’s hard to keep trusting them after they misreported statistical significance on the cardiac data last December. Hopefully Linda Marban is fired. Shorts got annihilated and that was ugly, even if shorting rare disease companies is a rough thing to do. @adamfeuerstein is just reporting what FDA reviewers are saying about the HOPE-3 data and the trust issues with the company. That’s not cancellation-worthy. He was one of Capricors first supporters and Is disappointed in them like many of us But attacking guys like @Elijahjstacy directly is a low for him . Give the guy a break, whether or not he’s on the company’s payroll as a consultant.
11
13
2,741
Mamdani’s October 7 post is a textbook move from someone who cannot stand to let Jewish victims stay the subject. He tosses out one line that Hamas murdered more than 1,100 Israelis and kidnapped 251 others, then pivots straight into the real message: Israel is committing genocide, running an apartheid occupation, bombing ambulances, and using American money to do it. The burned families, the festival massacre, the hostages still unaccounted for, all of it gets reduced to a throat-clearing exercise so he can indict the Jewish state. That is not commemoration. It is erasure dressed up as balance. An actual mayor of a city with the largest Jewish population outside Israel would have stopped at the dead and the kidnapped. Mamdani could not. His anti-Zionism required him to make the slaughter the footnote and the years of Israeli response the headline. He has spent his career treating Israel as uniquely criminal and Jewish self-defense as the original sin. This statement just made it official on the anniversary of the worst massacre of Jews since the Holocaust. He should resign. A mayor who uses the day Jews were hunted in their homes to prosecute the country those Jews fled to has no business holding the office.
This day is profoundly painful for so many New Yorkers. It marks three years since the horrific war crimes of October 7. On that day, Hamas killed more than 1,100 Israelis and abducted 251 others. We grieve alongside our many friends and neighbors who still carry that unthinkable loss. The suffering did not begin nor end that day. It instead continued through the Israeli government’s devastating, ongoing genocide in Gaza, in which it has killed more than 74,000 Palestinians—including more than 21,000 children. Even since the so-called ceasefire, more than 1,400 Palestinians have been killed. That suffering has intensified with every Israeli bomb dropped on ambulances waiting outside hospitals, every drone strike targeting a residential building or journalist, and every shipment of food aid turned away at a border crossing. Many New Yorkers are reckoning with this unbearable grief, and we mourn alongside them – all while knowing that our tax dollars fund these war crimes. Three years later, we must refuse to accept a world in which occupation and apartheid continue, where war crimes are met with impunity, and our federal government continues its complicity with every arms shipment. To honor the dead, we must fight for a world in which every person can live with freedom, safety, and dignity.
1
3
388
$NKTR is a warning to cut bait when management disappoints and I believe the stock will sell off as retail continues to abandon the story with no specialist funds in support On $CAPR I believed the data was strong but ignored my instincts and put blinders on when the NS lawsuit was initiated and management disappointed. 76% institutional ownership and several specialist funds showing up to buy the offering at $25 made me feel smart to hold If you aren’t willing to add $NKTR off this data than don’t justify holding it just cause your up. My 2 cents from a recent lesson learned the hard way
3
3
1,820
$CAPR Linda Marban will be vindicated if the the 24 month OLE data released tomorrow leads to another squeeze
5
28
3,152
$CAPR Linda covered the possibility of this exact scenario on an earlier conference call when Kristen Kluska asked her what happens if the FDA rejects LVEF as meaningful and issues a crl for the cardiomyopathy indication It’s buried in a Q and A session and provides Linda the legal cover for anyone suing about misleading remarks that drove the stock price to $40 off top line results We were all just greedy after the shorts got hurt and here we are now hoping for a miracle I mistakenly believed Linda and all of the analysts supported by institutions who bought the offering at $25 @seedy19tron warned us all but we live and learn You can be right about a short but still lose because it’s bad karma and the market is irrational
6
1
18
3,819
$CAPR is there a public comment among the appx. 200 posted on the FDAs website from a DMD patient in hope 2 or hope 3 saying that Capricor wasted their time traveling 4 times a year to treat them with a drug that doesn’t work? Bears should be blasting that all over X not regurgitating the info that blew up their accounts in December framed as FDA alignment based off briefing docs focused on SAP 1.1 Should be easy to find patients and caregivers blasting the company for selling them a fake bag of goods if it’s in fact true that the drug provides zero benefit
6
6
1
52
5,083
Markland55 retweeted
This bet was offered when Capricor was trading at $5 before release of phase 3 data Im willing to bet you he doesn’t have the sack or the stack to take my bet but my offer still stands Glad someone remembers this offer He’s all flash with zero substance but I like him- he provides comic relief
3
4
12
454
It is much easier to make an academic career out of criticizing other people’s work, than it is to actually do the work!
6
9
2
88
12,006
1/ $CAPR has been selling off on talk that the company might have been inadvertently unblinded before updating the HOPE-3 statistical plan. That story is getting more attention than it deserves. Here’s the actual situation. 2/ Capricor was very deliberate about this. They told investors back in 2025 that they would send the revised SAP to the FDA first, wait for feedback, and only unblind after that. That’s exactly what they did. 3/ Linda Marban has been clear on this. The company was not unblinded to the results before the SAP was submitted and approved. The changes were discussed with the FDA and they had their blessing. Everything was documented and shared with the agency. 4/ She even said this is probably just something the FDA wants to go over at the AdCom for transparency. Not because there’s an actual issue. 5/ On top of that, the change in how they analyzed the PUL 2.0 data (moving toward relative change and percent slowing instead of just absolute mean change) actually makes the results easier to understand. DMD patients start at very different levels of function, so showing how much the drug slowed decline compared to placebo (54% in this case) is more meaningful than raw point differences alone. 6/ PUL 2.0 itself is a solid, well-established tool. It was developed by an international group of clinicians and researchers, including Anna Mayhew and Eugenio Mercuri, and refined with better statistical methods to track upper limb function in DMD. 7/ The July 29 AdCom is there to look at these exact kinds of questions. The FDA will lay out any concerns they have, Capricor will walk through the timeline and procedures, and the panel will discuss it openly. That’s how these meetings work. 8/ At the end of the day HOPE-3 hit its main goal on PUL 2.0 and the key heart function measure, with results that line up with what they saw before. The noise around unblinding is mostly speculation that doesn’t line up with how the company actually ran the trial.
8
9
1
48
3,643
$abvx my thesis proved to be right on this one If $90 holds I expect a quick rebound to $105 and an offering announcement to follow
2
7
1,399
Markland55 retweeted
This was a snipe call @A_May_MD @seedy19tron should give some credit where credit is due
$ABVX with maintenance topline due late Q2 2026, expect near-term sell-the-news pressure Success has baked in optimism at 9.5B mkt cap; durability data risks underwhelming vs. high bars, despite de-risked biology CEO signals post-readout financing over immediate premium deal Technicals favor profit-taking and value likely compresses below $105 but @seedy19tron likes to gamble and i respect his conviction plays minus $capr short
2
1
5
743
$ABVX with maintenance topline due late Q2 2026, expect near-term sell-the-news pressure Success has baked in optimism at 9.5B mkt cap; durability data risks underwhelming vs. high bars, despite de-risked biology CEO signals post-readout financing over immediate premium deal Technicals favor profit-taking and value likely compresses below $105 but @seedy19tron likes to gamble and i respect his conviction plays minus $capr short
6
1
1
15
5,721
Markland55 retweeted
In under 30 days, U.S. forces will handle the Strait of Hormuz: neutralize the IRGC threats, clear the mines with precision, and get the oil tankers cruising again Meanwhile, FDA's Vinay Prasad wraps up his eventful run by end of April. Less regulatory fireworks, more smooth sailing for biotech. Lower oil drama = cheaper energy and calmer markets. Calmer FDA = fewer approval headaches. All that adds up to capital rotation back into innovation XBI cruising toward $136 by end of May Who else sees the setup? #XBI #biotech $abvx $qure $capr
2
10
912
In under 30 days, U.S. forces will handle the Strait of Hormuz: neutralize the IRGC threats, clear the mines with precision, and get the oil tankers cruising again Meanwhile, FDA's Vinay Prasad wraps up his eventful run by end of April. Less regulatory fireworks, more smooth sailing for biotech. Lower oil drama = cheaper energy and calmer markets. Calmer FDA = fewer approval headaches. All that adds up to capital rotation back into innovation XBI cruising toward $136 by end of May Who else sees the setup? #XBI #biotech $abvx $qure $capr
2
10
912
Arnold Ventures (founded by John Arnold) is laser-focused on FDA accountability. They demand rigorous Phase 3 RCTs, confirmed clinical benefits, and no more surrogate-endpoint shortcuts that fail patients (they’ve repeatedly called out eteplirsen-style approvals in DMD as exactly what’s wrong with the system). Deramiocel from Capricor checks every single box they want: 1. Not accelerated approval- full BLA seeking traditional approval. 2. Pivotal Phase 3 HOPE-3 trial (randomized, double-blind, placebo-controlled) just hit its primary endpoint. 3. Real, meaningful clinical outcomes: - 54% reduction in upper-limb function decline - 91% slowing of cardiac decline - Cardiac MRI data showing actual reduction in fibrotic segments (late gadolinium enhancement) This isn’t hype on a biomarker — it’s disease-modifying data on both skeletal muscle AND cardiomyopathy, the #1 cause of death in DMD. Exactly what Arnold Ventures has been begging the FDA to require: strong, confirmatory evidence BEFORE approval so patients and payers actually get value. PDUFA date: August 22, 2026 BLA already back under active review after the CRL was lifted this month If Arnold Ventures had to design the ideal next DMD therapy to restore trust in the approval process… this is it. $CAPR patients win. Evidence wins. The system wins. What do you think — will AV publicly praise this one? 👀 #DMD #Deramiocel #CAPR #RareDisease #FDA @DrMakaryFDA
2
7
1
32
2,440
@johnarnold please comment on the above I am a big fan of your work
1
219